Industry Symposium: Redefining your practice with infliximab biosimilar

Sponsored by

Prof Paul Kubler, Australia

Prof Yoshiya Tanaka, Japan
Prof Ki-Chul Shin, Korea
Prof Dae Hyun Yoo, Korea

The Celltrion Satellite Symposium, “Redefining your practice with infliximab biosimilar,” will highlight the role of biosimilar infliximab in expanding treatment options in rheumatologic diseases by introducing a novel subcutaneous formulation of infliximab.

The symposium will be chaired by Prof. Paul Kubler from Australia and will explore three key areas:

  • Biosimilar for the treatment of rheumatologic diseases
    Speaker: Prof. Yoshiya Tanaka from Japan will discuss how biosimilars can offer healthcare providers and patients greater treatment choice and value, better access to treatments and improved patient outcomes
  • Drug retention of infliximab in Rheumatoid arthritis: Data from KOBIO
    Speaker: Prof. Kichul Shin from South Korea will discuss the retention rate and safety of CT-P13 in patients with rheumatoid arthritis based on the data from KOBIO, the largest biologics and targeted therapy registry in South Korea.
  • Future of infliximab: subcutaneous formulation
    Speaker: Prof Daehyun Yoo from South Korea will reveal the latest clinical data on the efficacy and safety of subcutaneous infliximab.

The symposium will close with a panel discussion which will allow the audience to ask questions.


Wednesday 10 April 2019
Time Topic Speaker
1030 – 1035 Welcome and Introduction Prof Paul Kubler
1035 – 1055 Biosimilar for treatment of rheumatologic disease Prof Yoshiya Tanaka
1055 – 1115 Drug retention of infliximab in Rheumatoid arthritis: Data from KOBIO Prof Ki-Chul Shin
1115 – 1135 Future of infliximab: subcutaneous formulation Prof Dae Hyun Yoo
1135 – 1145 Panel Discussion All